Evora Biosciences develops EVOGEX, a proprietary discovery platform which combine the therapeutic properties of exosomes and cell penetrating peptides.

Our off-the-shelf exosomes are engineered for improved efficacy against immuno-inflammatory diseases.

Evora Bioscience heralded as one of France’s top 15 biotechs to invest in.
Challenges Magazine – March 2022

EVOGEX is Evora’s proprietary therapeutic discovery platform, based on patent-protected peptide-engineering of exosomes.

The aim of EVOGEX is to significantly enhance key properties of exosomes, to improve efficacy of exosome-based therapeutic approaches in immuno-inflammatory diseases.

Primary target : digestive fistula healing

Digestive fistula can be life-impairing for patients, and are linked to a variety of conditions, such as Crohn’s Disease, or surgical procedures, such as weight-loss procedures like sleeve gastrectomies.

For complex cases, currently available therapeutic options for patients and clinicians are unsatisfactory. Our lead product EVOGEX-Digest aims to dramatically improve patient outcomes in several GI-related indications.

Exosomes : powerful, efficient and customizable

Exosomes are small biological particle secreted by cells, from which they inherit some key therapeutic properties. Stem-cells derived exosomes, in particular, are able to virtually replicate the regenerative properties of their parent cells, while drastically simplifying logistics.

Compared to stem cells, exosome-based treatments offer simpler and more cost-efficient logistics, and greater ease of use for clinicians.

For patients, research has shown that exosomes have a more advantageous risk profile compared to stem cells : no donor rejection, no proliferation or differentiation risks.

Lastly, exosomes are perfectly suited for engineering, which enables significant improvements of their targeting , cell penetrating and cargo delivery properties.